JOURNEY BCS OXINIUM Knee Femoral Components, Catalog Numbers: 74021110, 74021111, 74021112, 7402...
FDA Device Recall #Z-0002-2019 — Class II — June 13, 2018
Recall Summary
| Recall Number | Z-0002-2019 |
| Classification | Class II — Moderate risk |
| Date Initiated | June 13, 2018 |
| Status | Ongoing |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Smith & Nephew, Inc. |
| Location | Memphis, TN |
| Product Type | Devices |
| Quantity | 42,050 units |
Product Description
JOURNEY BCS OXINIUM Knee Femoral Components, Catalog Numbers: 74021110, 74021111, 74021112, 74021113, 74021114, 74021115, 74021116, 74021117, 74021118, 74021119, 74021120, 74021121, 74021122, 74021123, 74021124, 74021125, 74021126, 74021127, 74021128, 74021129, 74021130, 74021131, 74021132, 74021133, 74021134, 74021135, 74021136, 74021137, 74021138, 74021139, 74021140, 74021141, 74021142, 74021143, 74021144, 74021145, 74021146, 74021147, 74021148, 74021149
Reason for Recall
The data in the National Joint Registry of England, Wales and Northern Ireland (NJREWNI) and Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR) indicate that the first generation JOURNEY BCS Knee System has a revision rate over 1.5 times the primary total knee arthroplasty device class average revision rates reported in those registries.
Distribution Pattern
Worldwide distribution, including US nationwide and Puerto Rico, Austria, United Arab Emirates, Australia, Belgium, Canada, China, Switzerland, Germany, Denmark, Finland, France, Great Britain, India, Spain, Italy, Netherlands, Portugal, Sweden, Venezuela, South Africa.
Lot / Code Information
All lots
Other Recalls from Smith & Nephew, Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| Z-0957-2026 | Class II | BIOSURE HA SCREW, 6MM x 20 MM. Threaded metalli... | Nov 24, 2025 |
| Z-1806-2025 | Class II | META-TAN LAG/COMPRESSION SCREW KIT 90MM/85MM, R... | Mar 18, 2025 |
| Z-0326-2025 | Class II | Tandem Intl Bipolar Cocr Shell/UHMWPE Liner, TI... | Oct 15, 2024 |
| Z-3171-2024 | Class II | DIAMOND POINT, BOTH ENDS K-WIRE, REF 128042, me... | Jul 9, 2024 |
| Z-3172-2024 | Class II | DIAMOND POINT, BOTH ENDS K-WIRE, REF 128062, me... | Jul 9, 2024 |
Frequently Asked Questions
Contact your healthcare provider and the device manufacturer immediately. Check whether your specific model number and lot number are included in the recall scope. For external devices, stop using the affected product and arrange a replacement. For implanted devices, do not panic — removal is typically not required unless the risk assessment clearly indicates it. Your physician will guide you based on your individual clinical situation and the FDA's recommended actions. Report any adverse effects you may have experienced to FDA MedWatch at 1-800-FDA-1088.
Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.
Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.
What Should You Do?
Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.